Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Liquid-biopsy Informed Platform Trial to Evaluate Treatment in CDK4/6-inhibitor Resistant ER+/HER2- Metastatic Breast Cancer

NCT05601440 is registered in ClinicalTrials.gov with Canadian Cancer Trials Group as lead sponsor.

NCT NCT05601440
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT05601440 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Liquid-biopsy Informed Platform Trial to Evaluate Treatment in CDK4/6-inhibitor Resistant ER+/HER2- Metastatic Breast Cancer
Lead sponsor
Canadian Cancer Trials Group
Phase
Phase 2
Overall status
Recruiting
Start date
June 13, 2023
Completion date
June 30, 2028
Enrollment
484 (estimated)
Sites
10

Conditions

As the registry lists them; a condition with its own page is linked.

breast cancer